Abstract
Background
 Obese women with preeclampsia have risky outcomes. This 
study assessed the efficacy and safety of the standard dose of intravenous
MgSo4
infusion
in
obese vs.
non-obese women
with
preeclampsia.
Materials and Methods
 This Randomized control trial was conducted in Women’s Health 
Hospital, Obstetrics and Gynecology Department, Assiut University
from January 2020 to August 2021. A total of 200 women with severe
preeclampsia
were
enrolled
and
randomly subdivided
based

on
body mass index into
two equal groups:
non-obese and
obese.
Both
groups received
a
loading dose
of
4 gm of MgSo4 infusion
as

4
grams of magnesium sulphate,
then a maintenance dose
of 1 gm
MgSo4
/hour for 24 hours. The
primary outcome was assessment
of
maternal
serum magnesium level at 30
minutes (after the
end
of
the
loading dose)
and 2,4 and 8 hours after the start. Also,
adverse
events
and maternal and fetal outcomes were recorded.
Results
 Based on classes of BMI, both groups had insignificant differences
regarding the
majority of baseline data.
The
non-obese group

had

significantly higher serum magnesium at different assessment
times during follow-up. Body mass index negatively correlated with